Pexidartinib
Pexidartinib
Pexidartinib (pronounced as pex-i-dar-ti-nib) is a medication used in the treatment of tenosynovial giant cell tumor (TGCT). It is a type of tyrosine kinase inhibitor that works by blocking certain proteins which help to keep the cells from growing.
Etymology
The name "Pexidartinib" is derived from the pharmaceutical naming convention, typically ending in "-tinib" for tyrosine kinase inhibitors.
Usage
Pexidartinib is used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and not amenable to improvement with surgery. It is administered orally.
Side Effects
Common side effects of Pexidartinib include liver damage, hair color changes, increased cholesterol level, decreased neutrophil count, decreased lymphocyte count, eye edema, decreased hemoglobin, rash, dysgeusia, and decreased phosphate.
Related Terms
- Tyrosine kinase inhibitor
- Tenosynovial giant cell tumor
- Liver damage
- Neutrophil
- Lymphocyte
- Hemoglobin
- Dysgeusia
External links
- Medical encyclopedia article on Pexidartinib
- Wikipedia's article - Pexidartinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski